Research Article| Volume 17, ISSUE 3, P197-204, November 1993

Download started.


Gynecologic complications of cyclic estrogen progestin therapy

      This paper is only available as a PDF. To read, Please Download here.


      We evaluated the long-term gynecologic risks of postmenopausal estrogen therapy in conjunction with cyclic, monthly progestin (progestin-estrogen replacement therapy, or PERT). Our medical record review showed that incidence of abnormal vaginal bleeding necessitating gynecologic procedures for evaluation was significantly higher (RR, 3.1; 95% CI, 2.1–4.5), as was the rate of endometrial biopsy (RR, 3.4; 95% CI, 2.3–5.1), among women receiving PERT than among women not receiving hormone therapy. We also identified a non-significant trend toward a higher rate of dilation and curettage (RR, 1.5; CI, 0.7-3.3) among women receiving PERT. However, rates of endometrial hyperplasia and hysterectomy were similarly low in both groups. PERT apparently protects women against these serious gynecologic consequences previously seen in women taking unopposed estrogen.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Maturitas
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ettinger B
        • Golditch IM
        • Friedman G
        Gynecologic consequences of long-term unopposed estrogen replacement therapy.
        Maturitas. 1988; 10: 271-282
        • Paganini-Hill A
        • Ross RK
        • Henderson BE
        Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study.
        Br J Cancer. 1989; 59: 445-447
        • Schiff I
        • Sela HK
        • Cramer D
        • Tulchinsky D
        • Ryan KJ
        Endometrial hyperplasia in women on cyclic or continuous estrogen regimens.
        Fertil Steril. 1982; 37: 79-82
        • Whitehead MI
        The effects of oestrogens and progestogens on the postmenopausal endometrium.
        Maturitas. 1978; 1: 87-98
        • Gambrell Jr, RD
        • Castaneda TA
        • Ricci CA
        Management of postmenopausal bleeding to prevent endometrial cancer.
        Maturitas. 1978; 1: 99-106
        • Persson I
        • Adami H-O
        • Bergkvist L
        • Lindgren A
        • Pettersson B
        • Hoover R
        • et al.
        Risk of endometrial cancer after treatment with oestrogens along or in conjunction with progestogens: results of a prospective study.
        Br Med J. 1989; 298: 147-151
        • Kleinbaum DG
        • Kupper LL
        • Morgenstern H
        Epidemiologic research: principles and quantitative methods.
        Lifetime Learning Publications, Belmont, California1982
        • Friedman AJ
        Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin replacement therapy for 2 years: a pilot study.
        Fertil Steril. 1989; 51: 526-528
        • Campbell S
        • McQueen J
        • Minardi J
        • Whitehead MJ
        The modifying effect of progestogen on the response of the post-menopausal endometrium to exogenous oestrogens.
        Postgrad Med J. 1978; 54: 59-64
        • Friedman AJ
        • Barbieri RL
        • Doubilet PM
        • Fine C
        • Schiff I
        A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri.
        Fertil Steril. 1988; 49: 404-409
        • Ross RK
        • Paganini-Hill A
        • Roy S
        • Chao A
        • Henderson BE
        Past and present preferred prescribing practices of hormone replacement therapy among Los Angeles gynecologists: possible implications for public health.
        Am J Public Health. 1988; 78: 516-519
        • Weinstein L
        • Bewtra C
        • Gallagher JC
        Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient.
        Am J Obstet Gynecol. 1990; 162: 1534-1542
        • Leather AT
        • Savvas M
        • Studd JWW
        Endometrial histology and bleeding patterns after 8 years of continuous combined estrogen and progestin therapy in postmenopausal women.
        Obstet Gynecol. 1991; 78: 1008-1010